TARS
Tarsus Pharmaceuticals Inc
NASDAQ: TARS · HEALTHCARE · BIOTECHNOLOGY
$60.67
-2.29% today
Updated 2026-04-29
Market cap
$2.61B
P/E ratio
—
P/S ratio
5.78x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$39 – $85
Volume
0.6M
Tarsus Pharmaceuticals Inc (TARS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-1.18M | $-3.67M | $-21.14M | $3.75M | $-49.03M | $-117.49M | $-83.03M | $-12.45M |
| Capital expenditures | $7000.00 | $175000.00 | $456000.00 | $586000.00 | $506000.00 | $5.50M | $1.57M | $9.86M |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $9000.00 | $18000.00 | $839000.00 | $8.46M | $13.46M | $19.83M | $27.82M | $41.72M |
| Free cash flow | $-1.19M | $-3.85M | $-21.59M | $3.16M | $-49.54M | $-123.00M | $-84.59M | $-22.31M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $110.18M | $3.18M | $-99.67M | — | — | — |